Bluesky Facebook Reddit Email

Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes

08.11.25 | JAMA Network

CalDigit TS4 Thunderbolt 4 Dock

CalDigit TS4 Thunderbolt 4 Dock simplifies serious desks with 18 ports for high-speed storage, monitors, and instruments across Mac and PC setups.

About The Study: In this study of patients with type 2 diabetes who had no prior eye disorders, patients prescribed semaglutide or tirzepatide had an increased risk of nonarteritic anterior ischemic optic neuropathy and other optic nerve disorders, although the overall risk was low. These findings highlight the need for close monitoring of these conditions.

Corresponding Author: To contact the corresponding author, Rong Xu, PhD, email rxx@case.edu .

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamanetworkopen.2025.26327)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.26327?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=081125

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

JAMA Network Open

Keywords

Article Information

Contact Information

JAMA Network Media Relations
JAMA Network
mediarelations@jamanetwork.org

How to Cite This Article

APA:
JAMA Network. (2025, August 11). Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes. Brightsurf News. https://www.brightsurf.com/news/L59XYX78/semaglutide-or-tirzepatide-and-optic-nerve-and-visual-pathway-disorders-in-type-2-diabetes.html
MLA:
"Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes." Brightsurf News, Aug. 11 2025, https://www.brightsurf.com/news/L59XYX78/semaglutide-or-tirzepatide-and-optic-nerve-and-visual-pathway-disorders-in-type-2-diabetes.html.